Skip to content

Wedbush’s Head Of Healthcare Equity Research Is Bullish On These Genetic-Medicine And Oncology Stocks

Dr. David Nierengarten, Managing Director and Head of Healthcare Equity Research at Wedbush Securities, sees potential in many biotech stocks, especially in the genetic-medicine and oncology spaces. For several specific genetic-medicine and oncology names that Nierengarten is particularly bullish on – including one company with a gene therapy for a rare retinal disease that causes significant vision loss (and sometimes complete blindness) in males – CLICK HERE.